Cargando…

Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome

BACKGROUND: Plasma concentrations of endocan, a proteoglycan preferentially expressed in the pulmonary vasculature, may represent a biomarker of lung (dys)function. We sought to determine whether the measurement of plasma endocan levels early in the course of acute respiratory distress syndrome (ARD...

Descripción completa

Detalles Bibliográficos
Autores principales: Orbegozo, Diego, Rahmania, Lokmane, Irazabal, Marian, Mendoza, Manuel, Annoni, Filippo, De Backer, Daniel, Creteur, Jacques, Vincent, Jean-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589715/
https://www.ncbi.nlm.nih.gov/pubmed/28884313
http://dx.doi.org/10.1186/s13613-017-0311-4
_version_ 1783262388202504192
author Orbegozo, Diego
Rahmania, Lokmane
Irazabal, Marian
Mendoza, Manuel
Annoni, Filippo
De Backer, Daniel
Creteur, Jacques
Vincent, Jean-Louis
author_facet Orbegozo, Diego
Rahmania, Lokmane
Irazabal, Marian
Mendoza, Manuel
Annoni, Filippo
De Backer, Daniel
Creteur, Jacques
Vincent, Jean-Louis
author_sort Orbegozo, Diego
collection PubMed
description BACKGROUND: Plasma concentrations of endocan, a proteoglycan preferentially expressed in the pulmonary vasculature, may represent a biomarker of lung (dys)function. We sought to determine whether the measurement of plasma endocan levels early in the course of acute respiratory distress syndrome (ARDS) could help predict risk of death or of prolonged ventilation. METHODS: All patients present in the department of intensive care during a 150-day period were screened for ARDS (using the Berlin definition). Endocan concentrations were measured at the moment of ARDS diagnosis (T0) and the following morning (T1). We compared data from survivors and non-survivors and data from survivors with less than 10 days of ventilator support (good evolution) and those who died or needed more than 10 days of mechanical ventilation (poor evolution). Results are presented as numbers (percentages), mean ± standard deviation or medians (percentile 25–75). RESULTS: Ninety-six consecutive patients were included [median APACHE II score of 21 (17–27) and SOFA score of 9 (6–12), PaO(2)/FiO(2) ratio 155 (113–206)]; 64 (67%) had sepsis and 51 (53%) were receiving norepinephrine. Non-survivors were older (66 ± 15 vs. 59 ± 18 years, p = 0.045) and had higher APACHE II scores [27 (22–30) vs. 20 (15–24), p < 0.001] and blood lactate concentrations at study inclusion [2.1 (1.3–4.0) vs. 1.5 (0.9–2.6) mmol/L, p = 0.024] than survivors, but PaO(2)/FiO(2) ratios [150 (116–207) vs. 158 (110–206), p = 0.95] were similar in the two groups. Endocan concentrations on the day after ARDS diagnosis were significantly higher in patients with poor evolution than in those with good evolution [12.0 (6.8–18.6) vs. 7.2 (5.4–12.5), p < 0.01]. CONCLUSION: Blood endocan concentrations early in the evolution of ARDS may be a useful marker of disease severity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-017-0311-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5589715
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-55897152017-09-27 Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome Orbegozo, Diego Rahmania, Lokmane Irazabal, Marian Mendoza, Manuel Annoni, Filippo De Backer, Daniel Creteur, Jacques Vincent, Jean-Louis Ann Intensive Care Research BACKGROUND: Plasma concentrations of endocan, a proteoglycan preferentially expressed in the pulmonary vasculature, may represent a biomarker of lung (dys)function. We sought to determine whether the measurement of plasma endocan levels early in the course of acute respiratory distress syndrome (ARDS) could help predict risk of death or of prolonged ventilation. METHODS: All patients present in the department of intensive care during a 150-day period were screened for ARDS (using the Berlin definition). Endocan concentrations were measured at the moment of ARDS diagnosis (T0) and the following morning (T1). We compared data from survivors and non-survivors and data from survivors with less than 10 days of ventilator support (good evolution) and those who died or needed more than 10 days of mechanical ventilation (poor evolution). Results are presented as numbers (percentages), mean ± standard deviation or medians (percentile 25–75). RESULTS: Ninety-six consecutive patients were included [median APACHE II score of 21 (17–27) and SOFA score of 9 (6–12), PaO(2)/FiO(2) ratio 155 (113–206)]; 64 (67%) had sepsis and 51 (53%) were receiving norepinephrine. Non-survivors were older (66 ± 15 vs. 59 ± 18 years, p = 0.045) and had higher APACHE II scores [27 (22–30) vs. 20 (15–24), p < 0.001] and blood lactate concentrations at study inclusion [2.1 (1.3–4.0) vs. 1.5 (0.9–2.6) mmol/L, p = 0.024] than survivors, but PaO(2)/FiO(2) ratios [150 (116–207) vs. 158 (110–206), p = 0.95] were similar in the two groups. Endocan concentrations on the day after ARDS diagnosis were significantly higher in patients with poor evolution than in those with good evolution [12.0 (6.8–18.6) vs. 7.2 (5.4–12.5), p < 0.01]. CONCLUSION: Blood endocan concentrations early in the evolution of ARDS may be a useful marker of disease severity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-017-0311-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-09-07 /pmc/articles/PMC5589715/ /pubmed/28884313 http://dx.doi.org/10.1186/s13613-017-0311-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Orbegozo, Diego
Rahmania, Lokmane
Irazabal, Marian
Mendoza, Manuel
Annoni, Filippo
De Backer, Daniel
Creteur, Jacques
Vincent, Jean-Louis
Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
title Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
title_full Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
title_fullStr Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
title_full_unstemmed Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
title_short Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
title_sort endocan as an early biomarker of severity in patients with acute respiratory distress syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589715/
https://www.ncbi.nlm.nih.gov/pubmed/28884313
http://dx.doi.org/10.1186/s13613-017-0311-4
work_keys_str_mv AT orbegozodiego endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT rahmanialokmane endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT irazabalmarian endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT mendozamanuel endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT annonifilippo endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT debackerdaniel endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT creteurjacques endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome
AT vincentjeanlouis endocanasanearlybiomarkerofseverityinpatientswithacuterespiratorydistresssyndrome